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Available online 11 February 2016The importance of the GABA-benzodiazepine receptor complex and its subtypes are increasingly recognised in
addiction. Using theα1/α5 benzodiazepine receptor PET radioligand [11C]Ro15 4513, we previously showed re-
duced binding in the nucleus accumbens and hippocampus in abstinent alcohol dependence. We proposed that
reduced [11C]Ro15 4513 binding in the nucleus accumbenswas amarker of addictionwhilst the reduction in hip-
pocampus and positive relationship with memory was a consequence of chronic alcohol abuse. To examine this
further we assessed [11C]Ro15 4513 binding in another addiction, opiate dependence, and used spectral analysis
to estimate contributions ofα1 andα5 subtypes to [11C]Ro15 4513 binding in opiate and previously acquired al-
cohol-dependent groups. Opiate substitutemaintained opiate-dependentmen (n=12) underwent an [11C]Ro15
4513 PET scan and compared with matched healthy controls (n = 13). We found a signiﬁcant reduction in
[11C]Ro15 4513 binding in the nucleus accumbens in the opiate-dependent compared with the healthy control
group. There was no relationship between [11C]Ro15 4513 binding in the hippocampus with memory. We
found that reduced [11C]Ro15 4513 binding was associated with reduced α5 but not α1 subtypes in the opi-
ate-dependent group. This was also seen in an alcohol-dependent group where an association betweenmemory
performance and [11C]Ro15 4513 binding was primarily driven by α5 and not α1 subtype. We suggest that re-
ducedα5 levels in the nucleus accumbens are associatedwith addiction sincewe have now shown this in depen-
dence to two pharmacologically different substances, alcohol and opiates.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Opiate addiction and its treatment is a global health issue. In the US,
1.8% of individuals over the age of 12 have tried heroin in their lifetime,
with 0.1% in the past month (National Survey of Drug Use and Health,
2012). In England, there are an estimated ~300,000 opiate and/or
crack users (8.67 per 1000 of 15 to 64 year olds; Statistics on Drug
Misuse: England, 2013). Many addicts relapse or ﬁnd it hard to achieve
abstinence, with only about 50% leaving treatment drug-free (Statistics
on Drug Misuse: England, 2013). To improve understanding andharmacology, Imperial College
.
gford-Hughes).
iomedical Engineering, King's
. This is an open access article undertreatment of opiate addiction, characterising its underlying neurobiolo-
gy is critical. Although heroin and other opioid agonists act on opioid re-
ceptors, preclinical evidence supports involvement of the GABA system
in their effects (Zetterström and Fillenz, 1990; Finlay et al., 1992 and
Creed et al., 2014). Endorphins or mu opiate agonists inhibit GABA-
ergic tonic inhibition of dopamine neuronal activity in the ventral teg-
mental area (VTA) resulting in increased dopamine neuronal ﬁring
and may thus contribute to the desire or compulsion to use opiates
(Johnson and North, 1992 and Ting-A-Kee and van der Kooy, 2012).
There are multiple subtypes of the GABA-benzodiazepine receptor
with the type of α subunit determining benzodiazepine and alcohol
sensitivity (Rudolph and Mohler, 2004). There is evidence that the α1,
α2 and α5 subtypes contribute to drug-liking and/or drug-seeking in
a variety of preclinical models with a range of substances of abuse
(Rudolph and Knoﬂach, 2011; Engin et al., 2012; Dixon et al., 2010;
June et al., 2001). Associations have also been reported betweenthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Demographic and clinical data.
Clinical variable Control
(opiate)
Opiate
dependent
Number 13 12
Age 40 ± 5 36.2 ± 7.6
Beck's depression inventory n/d 9.8 ± 7.9
Spielberger—State anxiety n/d 33.64 ± 7.9
Spielberger—Trait anxiety n/d 37.1 ± 9.8
Severity of Alcohol Dependence Questionnaire n/a n/a
Wechsler delayed verbal memory score n/d 10.2 ± 3.4
Length of abstinence (months) n/a n/a
Years of opiate use or alcohol dependence n/a 16 ± 6.8
Adjective checklist (opiate) withdrawal n/a 4 ± 3.8
Adjective checklist (opiate) agonist-like n/a 19.8 ± 3.9
n/a: not applicable; n/d: not done in whole sample.
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drug use disorders (Engin et al., 2012; Li et al., 2014). In addition, the
α5 subtype plays a role in learning and memory and its impairment
under the inﬂuence of alcohol (Nutt et al., 2007; Atack, 2011).
[11C]Ro15 4513 has a tenfold higher afﬁnity atα5 thanα1 receptors
(Lingford-Hughes et al., 2002).We have used [11C]Ro15 4513 to charac-
terise benzodiazepine receptor binding in man, particularly theα5 sub-
type, but due to the ubiquity of theα1 subtype, [11C]Ro15 4513 PET also
can detect this subtype (Myers et al., 2012). We previously reported
lower levels of [11C]Ro15 4513 binding in the nucleus accumbens of ab-
stinent alcoholics compared with controls (Lingford-Hughes et al.,
2012). We proposed that since the extrasynaptic α5 subtype provides
tonic inhibition, this lower level of receptors would contribute to insta-
bility of this critical dopaminergic brain region which in turn could lead
to enhanced drug consumption or seeking. We also reported that in al-
coholics, although not healthy controls,α5 receptor subtype availability
in the hippocampus positively correlated with verbal memory
performance.
This paper complements our [11C]Ro15 4513 PET study in alcohol-
ism by studying opiate dependence to assess whether lower levels of
[11C]Ro15 4513 binding are a marker of addiction. We hypothesised
that [11C]Ro15 4513 binding in opiate dependence would be lower in
the nucleus accumbens compared with controls. Since we suggested
the lower [11C]Ro15 4513 binding in the hippocampus was a conse-
quence of chronic alcohol abuse, we did not expect to see such a reduc-
tion in opiate addiction. Subsequent to our study in alcoholism
(Lingford-Hughes et al., 2012), we have developed the use of spectral
analysis to assess the contribution of α1 vs α5 subtypes to the
[11C]Ro15 4513 image (Myers et al., 2012). We report here for the ﬁrst
time levels of these subtype in opiate addiction and in alcoholism.
Materials and methods
Participants
Opiate-dependent males (DSM-IV) receiving substitute medication
(either methadone (n = 9; range 10–75 mg daily; mean daily dose
46.7 mg ± 19.7 mg) or buprenorphine (n = 3; 2.8 mg, 10 mg, 24 mg
daily; mean 12.3 mg ± 10.8 mg)) were recruited from local addiction
outpatient treatment services (see Table 1). The control group consisted
of 13 men recruited for this study or other studies (Myers et al., 2012;
Stokes et al., 2014) to match the opiate-dependent group. They had
nevermet criteria for abuse or dependence (DSM-IV) on alcohol or opi-
ates, although recreational non-dependent use of other illicit drugs
(eg cannabis, ecstasy) was permitted.
In the opiate-dependent group, none were or had been dependent
on any other drug including alcohol, cannabis, benzodiazepines or
stimulants, although occasionally cocaine, crack or amphetamine or
cannabis had been used, mostly when they were younger. All were ab-
stinent from alcohol and illicit drugs at the time of the study conﬁrmedwith negative urinalysis and breathalyser reading. Duration of opiate
use ranged from 9 to 30 years (mean ± SD, 16 ± 6.8) with most
smoking and injecting although 4 had never injected. The opiate-
dependent subjects were all current tobacco smokers except for one
who had stopped 6 weeks previously; in the control group, 2 were
smokers.
Individuals with clinical evidence of hepatic, cognitive or neurologi-
cal impairment or medical disorder were excluded. No individual had a
previous or current history of psychosis. Nonewere taking psychotropic
drugs, other than opiate substitute medication, except for one opiate-
dependent individual on mirtazapine.
Assessment: clinical
The opiate-dependent group was assessed using a semi-structured
questionnaire for all drugs of abuse, including alcohol and with Adjec-
tive Checklist (Jasinski, 1997) for their state at the time of the scan.
They underwent a similar assessment as in the alcohol-dependent
study which is described elsewhere (Lingford-Hughes et al., 2012) and
included Beck Depression Inventory (Beck et al., 1961), Spielberger
State–Trait Anxiety Inventory (Spielberger et al., 1970) and the
Wechsler Memory Scale and logical memory with immediate and 30-
min delayed recall of two stories. The controls recruited for other stud-
ies did not complete all these tests (n= 9; Stokes et al., 2014).
After complete description of the study to the subjects, written in-
formed consent was obtained. The study was approved by the local
Ethics Committees and by the UK Administration of Radioactive Sub-
stances Advisory Committee.
[11C]Ro15 4513 PET
We followed the same scanning protocol as described in Lingford-
Hughes et al. (2002). [11C]Ro15 4513 was synthesised by N-
methylation of the corresponding N-desmethyl derivative with
[11C]iodomethane. The product was puriﬁed by reverse phase HPLC
and the speciﬁc radioactivitywas ~14,000MBq/μmol at end of synthesis.
[11C]Ro15 4513 (mean ~ 475 MBq) in ~2 ml scans of opiate-depen-
dent individuals and all corresponding control subjects were performed
on a Siemens ECAT EXACT HR+ (CTI/Siemens, model 962; Knoxville,
TN, USA) scanner.
Blood sampling was carried out to produce a calibrated, metabolite
corrected plasma input function for quantiﬁcation of distribution vol-
ume with spectral analysis (Lingford-Hughes et al., 2012).
Image processing
PET emission data were corrected for attenuation and scatter using a
10-min transmission scan and reconstructed using Fourier rebinning
and 2D ﬁltered backprojection with a 2.0 mm kernel Ramp ﬁlter, into
24 dynamic frames (1 × 30, 4 × 15, 4 × 60, 2 × 150, 10 × 300 and
3 × 600 s). The ﬁnal reconstructed volume had voxel dimensions of
2.094 × 2.094 × 2.42 mm. All subjects also underwent T1-weighted
magnetic resonance imaging (MRI) with a Philips 1.5 T Gyroscan Intera
scanner (Philips, Best, The Netherlands), to provide anatomical images
to aid in region deﬁnition. A T1-weighted protocol was used to acquire
images viewed by a clinical Consultant Radiologist, and none were re-
ported as having signiﬁcant atrophy or abnormalities.
Reconstructed [11C]Ro15 4513 images were analysed on Sun work-
stations (Sun Microsystems, Mountain View, CA, USA) using Analyze
AVWversion 8.1 (Biomedical Imaging Resource, Mayo Clinic, Rochester,
MN; Robb and Hanson, 1991), Matlab 6.5 (The MathWorks, Inc.,
Cambridge, UK) and SPM5 (available via http://www.ﬁl.ion.ucl.ac.uk/
spm/).
Arterial blood input functions calibrated against discrete blood sam-
ples using a well counter and further corrected for parent fraction and
3A. Lingford-Hughes et al. / NeuroImage 132 (2016) 1–7plasma:blood ratio. Weighted summed PET images were used for rigid-
body co-registration to anatomical MRI data.
Maximum probability maps deﬁned in standard space (73 ROIs for
the earlier study with alcohol-dependent individuals, and 83 ROIs for
opiate dependence; Hammers et al., 2003; Gousias et al., 2008) were
ﬁtted after transformation into native space. Prior to regional sampling,
the goodness-of-ﬁt of each object map to the individual brain was
checked visually. The ROI samplingwas performed in Analyze 8.1 to ob-
tain the mean radioactivity concentration through all frames for all re-
gions in the atlas, and used to generate time-activity curves (TACs).
Spectral analysis
Spectral analysis is a basis function technique that uses a set of poly-
exponentials convolved with the parent plasma input function to ﬁt tis-
sue TACs with no prior assumption of model order (Cunningham and
Jones, 1993; Turkheimer et al., 1994). Although [11C]Ro15 4513 is rela-
tively selective for the GABA-benzodiazepine α5 receptor subtype,
there is measureable signal from the ubiquitous α1 subtype, which
can be partially quantiﬁed using band-pass spectral analysis (Myers
et al., 2012). [11C]Ro15 4513 VT can therefore be described as compris-
ing α1, α5 and non-displaceable components, Vα1 + Vα5 + VND.
Although it is not possible to directly quantify the contribution of
these components to the total signal, spectral analysis has been used
to provide estimates by separating Vα5 on the basis of slow kinetics.
One hundred exponential functionswere generated, with the decay pa-
rameter logarithmically distributed between 0.00006371 and 1 s−1
(Barros et al., 2010) and convolved with the arterial parent plasma
input function (CP) in order to generate a set of kinetic basis functions.
A non-negative least-squares algorithm was then used to ﬁt this over-
complete basis set to the measured data (CPET):
CPET tð Þ ¼
X100
i¼1
ϕie
−θi t⊗CP tð Þ
subject to ϕi≥0. Thus, an integral of the slow kinetic component of the
spectrum has been hypothesised to relate to GABAAα5 binding, andFig. 1. [11C]Ro15 4513 VT (mean ± SEM) in controls (n= 13) and opiate-dependent (n= 12)
addict group across all ROIs with a two-way ANOVA ((F(1, 1743) = 27.85; p b 0.0001), th
comparison correction (**).Vα5 is deﬁned by the limits a (0.00006371 s−1) and b (0.001 s−1):
Vα5 ¼
Xb
i¼a
ϕi
θi
Speciﬁc binding of [11C]Ro15 4513 to α1 is approximated by deﬁn-
ing the limits 0.0010–0.00040 s−1. Total volume of distribution (VT) is
deﬁned as the integral of all peaks in the spectrum.
Statistical analysis
Statistical analyses were conducted using GraphPad Prism (version
6 for Windows, GraphPad Software, San Diego, CA, USA, www.
graphpad.com). Relationships between [11C]Ro15 4513 volume of dis-
tributions VT, Vα1 and Vα5 and measures of memory were tested with
non-parametric Spearman's ranks correlation coefﬁcients. Repeated-
measures two-way ANOVA with ROI and group (alcohol or opiate-
dependent vs controls) was used to compare [11C]Ro15 4513
distribution volume in dependent individuals with that in controls. Re-
sults were corrected using post hoc Šidák correction for multiple
comparisons.
Results
Opiate dependence: [11C]Ro15 4513 VT
There was a signiﬁcant effect of group in the two-way ANOVA com-
paring [11C]Ro15 4513 VT in all ROIs between opiate-dependent and
healthy control groups, with lower VT in the opiate-dependent group
(F(1, 1743) = 27.85; p b 0.0001). Data from ROIs selected for their rel-
evance to addiction and [11C]Ro15 4513 VT binding are shown in Fig. 1.
After correction for multiple comparisons, the right nucleus accumbens
[11C]Ro15 4513 VT in the opiate-dependent group was the only ROI
where lower VT compared with healthy controls remained signiﬁcant
(t = 3.971; p b 0.01). No difference in nucleus accumbens volume, as
deﬁned by our atlas registration, was found between the groups.
There was a trend (p= 0.06) towards lower VT in the hippocampus ofControl 
Opiate 
Dependent
individuals in selected regions of interest (ROIs). There was signiﬁcantly lower VT in the
e right nucleus accumbens remained signiﬁcant (t = 3.971; p b 0.01) after multiple
*A B C
D E F
G H I
Fig. 2.Correlations of [11C]Ro15 4513VT,Vα1 andVα5 in thehippocampuswithWechsler Fig. 1 delayed verbalmemory score (WM;with 95% conﬁdence intervals) in controls (n=11;A,D,
F), alcohol-dependent (n= 8; B*, E, H; see Supplementary information for more details) and opiate-dependent (n= 12; C, F, I) individuals. (*p b 0.005).
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[11C]Ro15 4513 VT in the alcohol-dependent group (see below).
No signiﬁcant correlations were found between delayed verbal
memory performance and [11C]Ro15 4513 VT in opiate-dependent indi-
viduals in the hippocampus (see Fig. 2C). There was no signiﬁcant asso-
ciation of age or any clinical variables with VT. We did not see
differences in VT between methadone and buprenorphine or a relation-
ship between the prescribed dose of either substitute with VT, but the
study was not sufﬁciently powered for such analyses.
Opiate dependence: α1 and α5
There was no effect of group on the α1 component (F(1, 1743) =
0.1020; p = 0.7495), and no individual regions were prominent after
correction for multiple comparisons. There was, however, an effect of
group on the α5 component (F(1, 1660) = 4.760; p = 0.0293) with
lower α5 levels in the opiate-dependent group. The large inter-subject
variability resulted in no signiﬁcant differences being found in any indi-
vidual ROI after correction formultiple comparisons (see Fig. 3B,D,F). No
signiﬁcant correlations with memory performance were found (see
Fig. 2C,F,I).
Discussion
In this ﬁrst [11C]Ro15 4513 PET study of opiate dependence, we have
shown signiﬁcantly reduced levels of [11C]Ro15 4513VT in individuals on
opiate substitute medication compared with controls. A region of inter-
est analysis revealed a signiﬁcant reduction in the right nucleus accum-
bens. This complements our study in abstinent alcohol dependence
where we also reported reduced [11C]Ro15 4513 VT in the nucleusaccumbens. Using our spectral analytical approach to determine contri-
bution ofα1 andα5 binding to [11C]Ro15 4513VT, we found lower levels
of α5 subtype in nucleus accumbens in both alcohol and opiate depen-
dence compared with controls no signiﬁcant contribution from α1.
Given the different neuropharmacology of opiates and alcohol, our stud-
ies support our original proposal that lowα5 levels may be fundamental
to addiction rather than only associated with alcoholism.
We are not aware of any other in vivo imaging study of the
GABA-benzodiazepine receptor in opiate dependence in man. In
alcoholism using non-selective tracers, [11C]ﬂumazenil with PET or
[123I]iomazenil with SPET, have consistently shown a reduction in
GABA-benzodiazepine receptors particularly in the frontal cortex
(Abi-Dargham et al., 1998; Lingford-Hughes et al., 1998) whilst with
[11C]Ro15 4513, reductions are seen in limbic areas where binding is
high (Lingford-Hughes et al., 2002, 2012). It would be interesting to
know if a similar difference in distribution of [11C]ﬂumazenil vs
[11C]Ro15 4513 is seen in opiate dependence and the impact of the dif-
ferent opiate substitute medications. Whilst we did not see any differ-
ences between methadone and buprenorphine and [11C]Ro15 4513
binding, due to the small numbers we cannot exclude an interaction.
There are limited and inconsistent preclinical receptor binding stud-
ies to inform this clinical study. Direct competition between opiate sub-
stitute medication and [11C]Ro15 4513 is unlikely since opiate agonists
have low afﬁnity (~μM) for the [3H]GABA site (Dingledine et al., 1978;
Goldinger et al., 1981). Chronic morphine exposure has been reported
to increase [3H]GABA binding (Ticku and Huffman, 1980) and to in-
crease [3H]muscimol, [3H]ﬂunitrazepam or [3H]Ro15 1788 (ﬂumazenil)
binding in the cortex, which return to control levels in withdrawal
(Sivam et al., 1982; Lopez et al., 1990; Rocha et al., 1993). However,
other studies using active and passive or acute and chronic morphine
**
*
*
A B
C D
E F
Fig. 3. Comparison of [11C]Ro15 4513 VT, Vα1 and Vα5 (mean ± SEM) between controls (for alcohol: n= 11 (see Supplementary information for more details); for opiate n= 13) and
alcohol (n= 8; A, C, E) and opiate (n= 12; B, D, F)-dependent individuals in selected regions of interest (ROIs). *t= 3.713; p b 0.01.
5A. Lingford-Hughes et al. / NeuroImage 132 (2016) 1–7administration resulted in reduced or no changes in [3H]ﬂunitrazepam
binding in a range of cortical regions and hippocampus, although chron-
ic morphine did reduce sensitivity to GABA-enhancement of binding
(Smith et al., 1984, SivamandHo, 1982). Given the variability ofmodels,
length of opiate exposure and ligands for benzodiazepine receptor or
GABA site markers used, it is difﬁcult to extrapolate these ﬁndings to
our clinical [11C]Ro15 4513 PET study. The clinical importance of the in-
teraction between opiates and the GABA-ergic system suggests further
characterisation would be beneﬁcial. In addition, it would provide evi-
dence to understand if the lower level of [11C]Ro15 4513 binding in al-
cohol and opiate addiction reﬂect a vulnerability endophenotype to
addiction.
We have previously reported in our healthy control group that a cur-
rent or previous history of smokingwas associatedwith higher levels of
[11C]Ro15 4513 binding compared with those who had not smoked;
current smokers had lowest [11C]Ro15 4513 binding levels and were
more similar to controls than ex-smokers (Stokes et al., 2014). Since
all the opiate-dependent participants were current smokers, we areunable to distinguish between the roles of opiate and smoking depen-
dence to [11C]Ro15 4513 binding. In the alcohol-dependent group,
smokers had higher levels than the non-smokers, although there was
only one ex-smoker and two smokers. An [123I]iomazenil SPET study re-
ported higher binding in a non-smoker alcohol-dependent group com-
pared with a smoker alcohol-dependent group after one week of
abstinence but no differences were seen at four weeks (Staley et al.,
2005). Given the differences in length of abstinence from alcohol, it is
hard to directly compare the studies; however, both suggest that
smoking tobacco may alter GABA-benzodiazepine receptor availability.
If a reduction in α5 is critical in addiction, then why is tobacco smoking
not associated with reduced [11C]Ro15 4513 binding? Analogous to
studying alcohol dependence, where controls drink low amounts of
alcohol, comparing non-smokers, non-dependent ‘chippers’ and depen-
dent smokers will be required to determine impact of smoking versus
addiction on [11C]Ro15 4513 binding.
Characterising benzodiazepine subtypes in man is important to in-
form our understanding about its involvement in neuropsychiatric
6 A. Lingford-Hughes et al. / NeuroImage 132 (2016) 1–7disorders. Theα1 subtype is ubiquitous (~60% of all benzodiazepine re-
ceptors), is found in the synapse and is responsible for fast inhibitory
neurotransmission, whereas α5 is less abundant (~5%), extrasynaptic,
and responsible for tonic inhibition (Rudolph and Knoﬂach, 2011).
Each subtype is associated with particular roles such as sedation and
anti-convulsant effects for the α1 subtype and mediation of alcohol re-
ward and memory for α5. Using our spectral analytical approach, we
have demonstrated that the lower [11C]Ro15 4513 VT in the nucleus ac-
cumbens predominantly reﬂects lower α5 levels in alcohol and opiate
dependence. There are no preclinical studies of α1 and α5 subtypes in
opiate exposure. Whilst reduced α1 subtype protein and mRNA have
been reported consistently from chronic alcohol exposure in male rats,
by contrast increases or no change in binding of theα1 selective tracer,
[3H]zolpidem, have been reported (Grobin et al., 2000). Similarly,
alcohol-induced increases, decreases or no change have been reported
in α5 subunit protein or mRNA in the cortex (Devaud et al., 1995;
Charlton et al., 1997). It is difﬁcult to extrapolate such preclinical studies
to alcohol dependence inmanwith its greater complexity of alcohol ex-
posure and withdrawal.
In alcohol dependence, we previously reported that [11C]Ro15 4513
VT was signiﬁcant lower in the hippocampus compared with healthy
controls and that there was a positive relationship with delayed verbal
memory performance (Lingford-Hughes et al., 2012). We further
show here that this relationship between delayed verbal memory per-
formance is associated with [11C]Ro15 4513 Vα5 and not Vα1 in the hip-
pocampus in alcohol dependence. No such relationship was found in
opiate dependence or either control group. This is consistent with our
suggestion that hippocampalα5 levels here reﬂect adaptation to exces-
sive alcohol exposure (Lingford-Hughes et al., 2012) since none in opi-
ate group were alcohol dependent or had signiﬁcant history of alcohol
abuse. Therefore, we believe our conﬁrmation of α5 rather than α1
being associated with memory adds to the growing evidence of the im-
portance ofα5 in memory in neuropsychiatric disorders in man (Atack,
2011). Concerning the role of the α5 subtype in reward, whilst there is
preclinical evidence of lower α5 levels associated with reduced alcohol
preference and alcohol-seeking (June et al., 2001), there are no compa-
rable studies in opiate reward or dependence.
Whilst this is the ﬁrst study of [11C]Ro15 4513 in opiate dependence,
andwe report for the ﬁrst time delineation ofα1 andα5 in both alcohol
and opiate dependence, a limitation of our studies is that the numbers
are small. As a consequence of the loss of the scanner onwhich the alco-
hol dependent and their control groupwere studied, we had to perform
the study in opiate-dependent participants on a different scanner and
acquire an additional control group. Therefore, any inferences from
comparisons between alcohol and opiate dependence are cautiously
stated. As with our alcohol dependence study (Lingford-Hughes et al.,
2012), we think it unlikely that partial volume effects substantially con-
tribute to the reductions in [11C]Ro15 4513 binding seen in the opiate-
dependent group.We did not ﬁnd any differences in striatal volume be-
tween groups and have previously reported no atrophy in the striatum
in a similar group of opiate-dependent individuals (Reid et al., 2008).
In summary,we have shown lower [11C]Ro15 4513 binding associat-
ed with lower [11C]Ro15 4513 Vα5 in opiate dependence, particularly
in the nucleus accumbens. We have also shown lower α5 levels in the
nucleus accumbens in alcohol dependence, and suggest that such a re-
duction is fundamental to addiction and independent of the substance
of abuse. We propose that lower levels of α5 could result in less
GABA-ergic inhibitory activity on the mesolimbic dopaminergic system
resulting in its greater instability and thus greater response to
rewarding stimuli or salient cues. It remains to be elucidated whether
these lower levels contribute to a vulnerability endophenotype for ad-
diction more generally or result from substance abuse. Modulating the
α5 subtype presents an innovative target to probe substance abuse
and how it can be prevented or treated, particularly now agents selec-
tive for this receptor subtype are being developed for human use
(Atack, 2011).Acknowledgments
This work was supported by anMRC grant G400575. This work was
conducted in collaboration with Imanet, GE Healthcare. We thank all
the participants and radiographers for their support in conducting this
study.Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neuroimage.2016.02.005.References
Abi-Dargham, A., Krystal, J.H., Anjilvel, S., Scanley, B.E., Zoghbi, S., Baldwin, R.M., Rajeevan,
N., Ellis, S., Petrakis, I.L., Seibyl, J.P., Charney, D.S., Laruelle, M., Innis, R.B., 1998. Alter-
ations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT
and [123I]iomazenil. Am. J. Psychiatry 155, 1550–1555.
Atack, J.R., 2011. GABAA receptor subtype-selective modulators. II. α5-selective inverse
agonists for cognition enhancement. Curr. Top. Med. Chem. 11, 1203–1214.
Barros, D.A.R., Heckemann, R.A., Rosso, L., McGinnity, C.J., Keihaninejad, S., Gousias, I.S.,
Brooks, D.J., Duncan, J.S., Koepp, M.J., Turkheimer, F.E., Hammers, A., 2010. Investigat-
ing the reproducibility of the novel alpha-5 GABAA receptor PET ligand [11C]Ro15
4513. NeuroImage 52, S112.
Beck, A.T., Ward, C.H., Mendelson, M., Mock, J.E., Erbaugh, J., 1961. An inventory for mea-
suring depression. Arch. Gen. Psychiatry 4, 561–571.
Charlton, M.E., Sweetnam, P.M., Fitzgerald, L.W., Terwilliger, R.Z., Nestler, E.J., Duman, R.S.,
1997. Chronic ethanol administration regulates the expression of GABAA receptor
alpha 1 and alpha 5 subunits in the ventral tegmental area and hippocampus.
J. Neurochem. 68, 121–127.
Creed, M.C., Ntamati, N.R., Tan, K.R., 2014. VTA GABA neurons modulate speciﬁc learning
behaviors through the control of dopamine and cholinergic systems. Front. Behav.
Neurosci. 8, 8.
Cunningham, V.J., Jones, T., 1993. Spectral analysis of dynamic PET studies. J. Cereb. Blood
Flow Metab. 13, 15–23.
Devaud, L.L., Smith, F.D., Grayson, D.R., Morrow, A.L., 1995. Chronic ethanol consumption
differentially alters the expression of gamma-aminobutyric acidA receptor subunit
mRNAs in rat cerebral cortex: competitive, quantitative reverse transcriptase-
polymerase chain reaction analysis. Mol. Pharmacol. 48, 861–868.
Dingledine, R., Iversen, L.L., Breuker, E., 1978. Naloxone as a GABA antagonist: evidence
from iontophoretic, receptor binding and convulsant studies. Eur. J. Pharmacol. 47,
19–27.
Dixon, C.I., Morris, H.V., Breen, G., Desrivieres, S., Jugurnauth, S., Steiner, R.C., Vallada, H.,
Guindalini, C., Laranjeira, R., Messas, G., Rosahl, T.W., Atack, J.R., Peden, D.R., Belelli,
D., Lambert, J.J., King, S.L., Schumann, G., Stephens, D.N., 2010. Cocaine effects on
mouse incentive-learning and human addiction are linked to alpha2 subunit-
containing GABAA receptors. Proc. Natl. Acad. Sci. U. S. A. 107, 2289–2294.
Engin, E., Liu, J., Rudolph, U., 2012. α2-containing GABA(A) receptors: a target for the de-
velopment of novel treatment strategies for CNS disorders. Pharmacol. Ther. 136,
142–152.
Finlay, J.M., Damsma, G., Fibiger, H.C., 1992. Benzodiazepine-induced decreases in extra-
cellular concentrations of dopamine in the nucleus accumbens after acute and re-
peated administration. Psychopharmacology 106, 202–208.
Goldinger, A., Müller, W.E., Wollert, U., 1981. Inhibition of glycine and GABA receptor
binding by several opiate agonists and antagonists. Gen. Pharmacol. 12, 477–479.
Gousias, I.S., Rueckert, D., Heckemann, R.A., Dyet, L.E., Boardman, J.P., Edwards, A.D.,
Hammers, A., 2008. Automatic segmentation of brain MRIs of 2-year-olds into 83 re-
gions of interest. NeuroImage 40, 672–684.
Grobin, A.C., Papadeas, S.T., Morrow, A.L., 2000. Regional variations in the effects of chron-
ic ethanol administration on GABA(A) receptor expression: potential mechanisms.
Neurochem. Int. 37, 453–461.
Hammers, A., Allom, R., Koepp, M.J., Free, S.L., Myers, R., Lemieux, L., Mitchell, T.N., Brooks,
D.J., Duncan, J.S., 2003. Three-dimensional maximum probability atlas of the human
brain, with particular reference to the temporal lobe. Hum. Brain Mapp. 19, 224–247.
Jasinski, D.R., 1997. Assessment of the abuse potential of morphine-like drugs (methods
used in man). In Drug Addiction I: Morphine, Sedative/Hypnotic and Alcohol Depen-
dence. Handb. Exp. Pharmacol. 45, 197–258.
Johnson, S.W., North, R.A., 1992. Opioids excite dopamine neurons by hyperpolarization
of local interneurons. J. Neurosci. 12, 483–488.
June, H.L., Harvey, S.C., Foster, K.L., McKay, P.F., Cummings, R., Garcia, M., Mason, D., Grey,
C., McCane, S., Williams, L.S., Johnson, T.B., He, X., Rock, S., Cook, J.M., 2001.
GABA(A) receptors containing (alpha)5 subunits in the CA1 and CA3 hippocampal
ﬁelds regulate ethanol-motivated behaviors: an extended ethanol reward circuitry.
J. Neurosci. 21, 2166–2177.
Li, D., Sulovari, A., Cheng, C., Zhao, H., Kranzler, H.R., Gelernter, J., 2014. Association of
gamma-aminobutyric acid A receptor α2 gene (GABRA2) with alcohol use disorder.
Neuropsychopharmacology 39 (4), 907–918.
Lingford-Hughes, A.R., Acton, P.D., Gacinovic, S., Suckling, J., Busatto, G.F., Boddington,
S.J.A., Bullmore, E., Woodruff, P.W., Costa, D.C., Pilowsky, L.S., Ell, P.J., Marshall, E.J.,
Kerwin, R.W., 1998. Reduced levels of the GABA-benzodiazepine receptor in alcohol
dependency in the absence of grey matter atrophy. Br. J. Psychiatry 173, 16–122.
7A. Lingford-Hughes et al. / NeuroImage 132 (2016) 1–7Lingford-Hughes, A., Hume, S.P., Feeney, A., Hirani, E., Osman, S., Cunningham, V.J., Pike,
V.W., Brooks, D.J., Nutt, D.J., 2002. Imaging the GABA-benzodiazepine receptor sub-
type containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission
tomography. J. Cereb. Blood Flow Metab. 22, 878–889.
Lingford-Hughes, A., Reid, A.G., Myers, J., Feeney, A., Hammers, A., Taylor, L.G., Rosso, L.,
Turkheimer, F., Brooks, D.J., Grasby, P., Nutt, D.J., 2012. A [11C]Ro15 4513 PET study
suggests that alcohol dependence in man is associated with reduced α5 benzodiaze-
pine receptors in limbic regions. J. Psychopharmacol. 26, 273–281.
Lopez, F., Miller, L.G., Thompson, M.L., Schatzki, A., Chesley, S., Greenblatt, D.J., Shader, R.I.,
1990. Chronic morphine administration augments benzodiazepine binding and
GABAA receptor function. Psychopharmacology 101, 545–549.
Myers, J.F., Rosso, L., Watson, B.J., Wilson, S.J., Kalk, N.J., Clementi, N., Brooks, D.J., Nutt, D.J.,
Turkheimer, F.E., Lingford-Hughes, A.R., 2012. Characterisation of the contribution of
the GABA-benzodiazepine α1 receptor subtype to [(11)C]Ro15-4513 PET images.
J. Cereb. Blood Flow Metab. 32, 731–744.
National Survey of Drug Use and Health, 2012. http://www.drugabuse.gov/national-
survey-drug-use-health.
Nutt, D.J., Besson, M., Wilson, S.J., Dawson, G.R., Lingford-Hughes, A.R., 2007. Selective
blockade of alcohol's amnestic actions by anα5 subtype- benzodiazepine receptor in-
verse agonist. Neuropharmacology 53, 810–820.
Reid, A.G., Daglish, M.R.C., Kempton, M., Williams, T.M., Watson, B., Nutt, D.J., Lingford-
Hughes, A., 2008. Reduced grey matter volume in opiate dependence may
Be explained By degree of alcohol use: a voxel-based morphometry study.
J. Psychopharmacol. 22 (1), 7–10.
Robb, R.A., Hanson, D.P., 1991. A software system for interactive and quantitative visual-
ization of multidimensional biomedical images. Australas. Phys. Eng. Sci. Med. 14,
9–30.
Rocha, L., Tatsukawa, K., Chugani, H.T., Engel Jr., J., 1993. Benzodiazepine receptor binding
following chronic treatment with naloxone,morphine andmet-enkephalin in normal
rats. Brain Res. 612, 247–252.
Rudolph, U., Knoﬂach, F., 2011. Beyond classical benzodiazepines: novel therapeutic po-
tential of GABAA receptor subtypes. Nat. Rev. Drug Discov. 10, 685–697.
Rudolph, U., Mohler, H., 2004. Analysis of GABAA receptor function and dissection of the
pharmacology of benzodiazepines and general anesthetics through mouse genetics.
Annu. Rev. Pharmacol. Toxicol. 44, 475–498.Sivam, S.P., Ho, I.K., 1982. Inﬂuence of morphine dependence on GABA-stimulated benzo-
diazepine binding to mouse brain synaptic membranes. Eur. J. Pharmacol. 79,
335–336.
Sivam, S.P., Nabeshima, T., Ho, I.K., 1982. An analysis of GABA receptor changes in the dis-
crete regions of mouse brain after acute and chronic treatments with morphine.
J. Neurochem. 39, 933–939.
Smith, J.E., Co, C., Lane, J.D., 1984. Limbic muscarinic cholinergic and benzodiazepine re-
ceptor changes with chronic intravenous morphine and self-administration.
Pharmacol. Biochem. Behav. 20, 443–450.
Spielberger, C., Gorsuch, R.L., Lushene, R.E., 1970. Manual for the State–Trait Anxiety In-
ventory. Consulting Psychologist Press, Palo Alto.
Staley, J.K., Gottschalk, C., Petrakis, I.L., Gueorguieva, R., O'Malley, S., Baldwin, R., Jatlow, P.,
Verhoeff, N.P., Perry, E., Weinzimmer, D., Frohlich, E., Ruff, E., van Dyck, C.H., Seibyl,
J.P., Innis, R.B., Krystal, J.H., 2005. Cortical gamma-aminobutyric acid type
A-benzodiazepine receptors in recovery from alcohol dependence: relationship to
features of alcohol dependence and cigarette smoking. Arch. Gen. Psychiatry 62,
877–888.
Statistics on Drug Misuse: England, 2013. http://www.hscic.gov.uk/catalogue/PUB12994/
drug-misu-eng-2013-rep.pdf.
Stokes, P.R., Myers, J.F., Kalk, N.J., Watson, B.J., Erritzoe, D., Wilson, S.J., Cunningham, V.J.,
Barros, D.R., Hammers, A., Turkheimer, F.E., Nutt, D.J., Lingford-Hughes, A.R., 2014.
Acute increases in synaptic GABA detectable in the living human brain: a
[11C]Ro15-4513 PET study. NeuroImage 99, 158–165.
Ticku, M.K., Huffman, R.D., 1980. The effects of acute and chronic morphine administra-
tion on GABA receptor binding. Eur. J. Pharmacol. 68, 97–106.
Ting-A-Kee, R., van der Kooy, D., 2012. The neurobiology of opiatemotivation. Cold Spring
Harb. Perspect. Med. 2 (10), a012096.
Turkheimer, F., Moresco, R.M., Lucignani, G., Sokoloff, L., Fazio, F., Schmidt, K., 1994. The
use of spectral analysis to determine regional cerebral glucose utilization with posi-
tron emission tomography and [18F]ﬂuorodeoxyglucose: theory, implementation,
and optimization procedures. J. Cereb. Blood Flow Metab. 14 (3), 406–422.
Zetterström, T., Fillenz, M., 1990. Local administration of ﬂurazepam has different effects
on dopamine release in striatum and nucleus accumbens: a microdialysis study.
Neuropharmacology 29, 129–134.
